-

Gamida Cell to Participate in Upcoming Investor Conferences

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases, today announced that company management will participate in three upcoming virtual investor conferences in September:

H.C. Wainwright 22nd Annual Global Investment Conference
Date: Monday, September 14, 2020
Presentation: 11:00 a.m. ET

Cantor Virtual Global Healthcare Conference
Date: Thursday, September 17, 2020
Presentation: 4:00 p.m. ET

Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit
Date: Monday, September 21, 2020
Fireside Chat: 4:10 p.m. ET

A live webcast of each presentation will be available in the “Investors & Media” section of the Gamida Cell website, www.gamida-cell.com, and will be available for at least 14 days following the event.

About Gamida Cell
Gamida Cell is an advanced cell therapy company committed to finding cures for blood cancers and serious blood diseases. We harness our cell expansion platform to create therapies with the potential to redefine standards of care in areas of serious medical need. For additional information, please visit www.gamida-cell.com or follow Gamida Cell on LinkedIn or Twitter at @GamidaCellTx.

Contacts

Jaren Irene Madden
jaren@gamida-cell.com
1-617-286-6264

Matthew Corcoran (media)
mcorcoran@tenbridgecommunications.com
1-617-866-7350

Industry:

Gamida Cell Ltd.

NASDAQ:GMDA
Release Summary
Gamida Cell will participate in three upcoming virtual investor conferences in September.
Release Versions
English
$Cashtags
$GMDA

Contacts

Jaren Irene Madden
jaren@gamida-cell.com
1-617-286-6264

Matthew Corcoran (media)
mcorcoran@tenbridgecommunications.com
1-617-866-7350

Social Media Profiles
Gamida Cell on LinkedIn
Gamida Cell on Twitter
More News From Gamida Cell Ltd.

Gamida Cell Announces Closing of $25 Million Financing With Highbridge

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the global leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, announced the closing of a senior secured convertible term loan of $25 million with certain funds managed by Highbridge Capital Management, LLC (collectively, “Highbridge”). Pursuant to the loan agreement, Gamida Cell’s wholly-owned subsidiary, as borrower, will draw down $25 million from the faci...

Gamida Cell to Present Corporate Highlights at Multiple Upcoming Investor Conferences

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today announced that members of the management team will present at the following upcoming investor conferences: 34th Annual Piper Sandler Healthcare Conference, November 29, 2022 with a fireside chat at 1:00 p.m. ET. Evercore ISI Healthcare Conference, December 1, 2022 with a fireside chat at 2:15 p.m....

Gamida Cell Provides Regulatory Update on Omidubicel

BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematological and solid cancers and other serious diseases, today provided an update on recent interactions with the U.S. Food and Drug Administration (FDA) relating to the company’s Biologics License Application (BLA) for omidubicel, the company’s advanced cell therapy candidate for allogeneic hematopoietic stem cell transplant. As part of its ongoing BLA revi...
Back to Newsroom